(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.
Publication
, Journal Article
Perng, P; Marcus, C; Subramaniam, RM
Published in: AJR Am J Roentgenol
August 2015
OBJECTIVE: Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of (18)F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION: FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
AJR Am J Roentgenol
DOI
EISSN
1546-3141
Publication Date
August 2015
Volume
205
Issue
2
Start / End Page
259 / 270
Location
United States
Related Subject Headings
- Tomography, X-Ray Computed
- Survival Analysis
- Radiopharmaceuticals
- Programmed Cell Death 1 Receptor
- Prognosis
- Predictive Value of Tests
- Positron-Emission Tomography
- Nuclear Medicine & Medical Imaging
- Neoplasm Staging
- Multimodal Imaging
Citation
APA
Chicago
ICMJE
MLA
NLM
Perng, P., Marcus, C., & Subramaniam, R. M. (2015). (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. AJR Am J Roentgenol, 205(2), 259–270. https://doi.org/10.2214/AJR.14.13575
Perng, Powell, Charles Marcus, and Rathan M. Subramaniam. “(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.” AJR Am J Roentgenol 205, no. 2 (August 2015): 259–70. https://doi.org/10.2214/AJR.14.13575.
Perng P, Marcus C, Subramaniam RM. (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. AJR Am J Roentgenol. 2015 Aug;205(2):259–70.
Perng, Powell, et al. “(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.” AJR Am J Roentgenol, vol. 205, no. 2, Aug. 2015, pp. 259–70. Pubmed, doi:10.2214/AJR.14.13575.
Perng P, Marcus C, Subramaniam RM. (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. AJR Am J Roentgenol. 2015 Aug;205(2):259–270.
Published In
AJR Am J Roentgenol
DOI
EISSN
1546-3141
Publication Date
August 2015
Volume
205
Issue
2
Start / End Page
259 / 270
Location
United States
Related Subject Headings
- Tomography, X-Ray Computed
- Survival Analysis
- Radiopharmaceuticals
- Programmed Cell Death 1 Receptor
- Prognosis
- Predictive Value of Tests
- Positron-Emission Tomography
- Nuclear Medicine & Medical Imaging
- Neoplasm Staging
- Multimodal Imaging